Clinical Trials Logo

Clinical Trial Summary

Headaches in children are very common and are a source of significant distress for the patient and their family. Migraines are the most common headache disorder in children and are associated with episodic pain and other symptoms such as nausea and sensitivity to light and sound that can impair a child's ability to participate in daily activities and lead to missed school or parental missed work. When home treatment fails to relieve symptoms, children often seek care in the emergency department (ED) where a limited number of treatment options exist; while largely effective, these rescue treatments currently all require needle insertion of an intravenous line, take time to administer, result in prolonged ED stays, and have potential unpleasant side effects. In adult patients, a number of studies suggest that lidocaine, a local anesthetic administered intranasally, may provide relief of migraine and migraine-like headache pain in minutes. This approach has the benefit of working quickly, not requiring a needle, and having fewer side effects as the medication acts locally on nerves in the nose. Intranasal lidocaine has not yet been studied in children for this purpose. This study will compare the use of intranasal lidocaine to placebo. The goal of this pilot study is to provide information to inform the sample size calculation for the definitive randomized controlled trial that will aim to measure the efficacy of intranasal lidocaine as an analgesic option for children age 7 years and older who present to the Pediatric ED with a chief complaint of migraine or post traumatic headache with migraine-like features. Secondary objectives will be to report on the frequency and severity of rebound headache between the two treatment groups, adverse events of the study drug, as well as the impact on healthcare utilization measures.The investigators hypothesize that children receiving intranasal lidocaine will have faster and more effective pain recovery compared to children receiving placebo and will be less likely to require the standard therapy for migraine headache. Given very few side effects reported in adult studies and the relatively benign nature of those reported, the investigators do not expect any major safety concerns in the study. It is also hypothesized that intranasal lidocaine will lead to shorter ED visits, thus reducing use of staff and hospital resources and saving money for the healthcare system as a whole.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03806595
Study type Interventional
Source University of British Columbia
Contact
Status Completed
Phase Phase 1
Start date July 3, 2019
Completion date December 3, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT06068751 - Aerobic Exercise and Neck Exercises in Pediatric Migraine Treatment N/A
Terminated NCT03885154 - Valproic Acid and Dihydroergotamine as Abortive Therapy in Pediatric Migraine Phase 2
Recruiting NCT05814497 - Supraspinal Processing of Sensory Aspects of Pain N/A
Not yet recruiting NCT06277063 - nVNS for the Prevention and Treatment of Primary Headache N/A
Recruiting NCT03984045 - SPG Block for Acute Pediatric Migraine Phase 3
Recruiting NCT06182098 - Intravenous Fluids in Pediatric Migraine N/A
Completed NCT04968093 - Mindfulness for Adolescents for CM and HFEM N/A
Withdrawn NCT04466826 - Transnasal Sphenopalatine Ganglia Block for Management of Chronic Migraines in Pediatric Patients Phase 2
Recruiting NCT05969990 - Tryptophan Metabolites in Pediatric Migraine
Not yet recruiting NCT06180577 - A Survey Study to Assess the Accessibility of the Nerivio Device at School
Completed NCT04537429 - A Study in Children and Young People With Migraine to Learn What the Body Does to Eptinezumab Phase 1